Clinical Interests:Treatment for cancer, geriatric disease, and the difficult and complicated cases
Education:He graduated from Hubei University of traditional Chinese medicine with a master's degree in 1992 and Shanghai University of traditional Chinese medicine with a doctor's degree in 1998; He is a Postdoctoral researcher in Guangzhou University of traditional Chinese Medicine from 2003 to 2005
Awards and Honors
Second prize of China University Science and Technology Award;
First prize of science and technology progress of Guangdong Province;
Second prize of scientific and technological achievements of Shanghai Health Bureau。
"The Famous TCM Doctor in Guangdong Province" awarded by the Government of Guangdong Province;
"The Best TCM Doctor in Guangdong" awarded by Guangdong traditional Chinese Medicine Association.
Professional memberships
Executive Vice President of Geriatric Branch of China Medical Association of Minorities;
Vice chairman of Professional Committee of Research on anti-tumor drugs of Chinese Association of Traditional Chinese Medicine;
Executive Council Member of the Board of Specialty Committee of Cancer Palliative Treatment of World Frederation of Chinese Medicine Societies;
Council Member of Chinese Association of Integrative Medicine ;
Vice president of Guangdong Association of Integrative Medicine;
Chairman of Specialty Committee of Geriatric Disease of Guangdong Chinese Medicine Association;
Vice President of Traditional Medicine Association of Guangdong Province
Publications
1:TNF-α derived from M2 tumor-associated macrophages promotes epithelial-mesenchymal transition and cancer stemness through the Wnt/β-catenin pathway in SMMC-7721 hepatocellular carcinoma cells. Exp Cell Res.2019 May 1;378(1):41-50.
2: Jianpi-Huayu Formula Inhibits Development of Hepatocellular Carcinoma by Regulating Expression of miR-602, Which Targets the RASSF1A Gene. Integr Cancer Ther. 2020 Jan-Dec;19:1534735419900804.
3:Jianpi Huayu Decoction Attenuates the Immunosuppressive Status of H 22 Hepatocellular Carcinoma-Bearing Mice: By Targeting Myeloid-Derived Suppressor Cells. Front Pharmacol. 2020 Feb 18;11:16.
4: miR-602 Mediates the RASSF1A/JNK Pathway, Thereby Promoting Postoperative Recurrence in Nude Mice with Liver Cancer. Onco Targets Ther. 2020 Jul 10;13:6767-6776.
5：Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail. J Tradit Chin Med. 2013 Apr;33(2):176-80.
6：MiR-570 inhibited the cell proliferation and invasion through directly targeting B7-H1 in hepatocellular carcinoma. Tumour Biol. 2015 Nov;36(11):9049-57.
7：miR-570 Inhibits Proliferation, Angiogenesis, and Immune Escape of Hepatocellular Carcinoma. Cancer Biother Radiopharm. 2018 Aug;33(6):252-257.
8：Mechanism of Bushen Jianpi decoction in preventing and treating osteoporosis caused by aromatase inhibitors in breast cancer treatment. Cancer Biomark. 2017;18(2):183-190
9：The emerging roles of exosomal circRNAs indiseases. Clinical and Translational Oncology.https://doi.org/10.1007/s12094-020-02485-6
10：Reconstruction of Alzheimer’s Disease Cell Model In Vitro via Extracted Peripheral Blood Molecular Cells from a Sporadic Patient. Stem Cells International.https://doi.org/10.1155/2020/8897494
11. Personalized Body Constitution Inquiry Based on Machine Learning. Journal of Healthcare Engineering.https://doi.org/10.1155/2020/8834465
